Chronic Cough - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Cough - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chronic Cough - Pipeline Review, H2 2016', provides an overview of the Chronic Cough pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Cough
- The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects
- The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Cough

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Cough Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Cough - Overview 8
Pipeline Products for Chronic Cough - Comparative Analysis 9
Chronic Cough - Therapeutics under Development by Companies 10
Chronic Cough - Therapeutics under Investigation by Universities/Institutes 11
Chronic Cough - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Chronic Cough - Products under Development by Companies 14
Chronic Cough - Products under Investigation by Universities/Institutes 15
Chronic Cough - Companies Involved in Therapeutics Development 16
Afferent Pharmaceuticals, Inc. 16
AstraZeneca Plc 17
Conrig Pharma ApS 18
GlaxoSmithKline Plc 19
Glenmark Pharmaceuticals Ltd. 20
GW Pharmaceuticals Plc 21
NeRRe Therapeutics Ltd 22
Patara Pharma, Inc. 23
Pila Pharma AB 24
Chronic Cough - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 33
AF-219 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
cromolyn sodium - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GRC-17536 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GSK-2339345 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lesogaberan - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NEO-5937 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
orvepitant maleate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
S-1226 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ST-015 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
XEND-0501 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Chronic Cough - Dormant Projects 51
Chronic Cough - Discontinued Products 52
Chronic Cough - Product Development Milestones 53
Featured News & Press Releases 53
Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis 53
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 54
May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors 56
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 56
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for Chronic Cough, H2 2016 8
Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 16
Chronic Cough - Pipeline by AstraZeneca Plc, H2 2016 17
Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2016 18
Chronic Cough - Pipeline by GlaxoSmithKline Plc, H2 2016 19
Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 20
Chronic Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016 21
Chronic Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016 22
Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2016 23
Chronic Cough - Pipeline by Pila Pharma AB, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 32
Chronic Cough - Dormant Projects, H2 2016 51
Chronic Cough - Discontinued Products, H2 2016 52